PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
P/E ratio for PeptiDream Inc. (4587.T)
P/E ratio as of 2023: 63.51
According to PeptiDream Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 63.51. At the end of 2022 the company had a P/E ratio of 35.70.
P/E ratio history for PeptiDream Inc. from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 63.51 |
| 2022 | 35.70 |
| 2021 | 90.97 |
| 2020 | 148.03 |
| 2019 | -717.49 |
| 2018 | 254.25 |
| 2017 | 238.20 |
| 2016 | 214.89 |
| 2015 | 213.69 |
| 2014 | 186.81 |
| 2013 | 724.16 |
| 2012 | 705.12 |
| 2011 | 9872.63 |